Based on international guidelines published in 2016, this app is a practical, step-by-step guide for the prophylaxis and treatment of venous thromboembolism in patients with cancer, including:
• Prophylaxis in hospitalized and ambulatory patients
• Treatment guidance for both non-catheter and catheter-related VTE
• Specific guidance related to various cancer and treatment types
• Early, short-term, and long-term treatment guidance
This treatment algorithm is intended for physicians and other healthcare professionals treating patients with cancer. It should not replace clinical judgement. It is based on clinical practice guidelines published in 2016:
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA, Pabinger I, Solymoss S, Douketis J, Kakkar A. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2016;17(10):e452-e466.
While these guidelines rely on the best available evidence at the time of publication, the clinician is advised to use clinical judgement when making decisions about prophylaxis and treatment of venous thromboembolism in patients with cancer.
APP AUTHORS / STEERING COMMITTEE
Professor Dominique Farge (France) (Co-chairperson)
Professor James Douketis (Canada) (Co-chairperson)
Professor Henri Bounameaux (Switzerland)
Professor Benjamin Brenner (Israel)
Dr Francis Cajfinger (France)
Dr Philippe Debourdeau (France)
Dr Alok A Khorana (United States)
Professor Ingrid Pabinger (Austria)
Dr Susan Solymoss (Canada)
The International Initiative on Thrombosis and Cancer (ITAC-CME) is the international section of the Groupe Francophone Thrombose et Cancer (GFTC). A multidisciplinary group, the members of ITAC-CME are clinicians and researchers from across the globe, led by a core group of GFTC members. The mandate of ITAC-CME is to publish results of educational knowledge transfer research findings.
Through education of physicians, nurses, and allied health professionals, ITAC-CME is committed to disseminating relevant and peer-reviewed prophylaxis and treatment guidelines for VTE in cancer that will help to reduce a substantial economic burden on health care systems and improve the lives of millions of patients worldwide.